UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
------------------
For the month of July 2004
Commission File Number: 001-31368
SANOFI-SYNTHELABO
(Translation of registrant's name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82-________
This Report on Form 6-K shall be deemed to be incorporated by reference
into Sanofi-Synthelabo's Registration Statement on Form F-4 (Registration No.
333-112314), as post-effectively amended and declared effective on May 13, 2004
by the United States Securities Exchange Commission, and the related prospectus,
dated April 9, 2004, and the prospectus supplement, dated May 27, 2004, each
filed pursuant to Rule 424(b) under the United States Securities Act of 1933, as
amended, and shall be part thereof from the date on which this Report is filed,
to the extent not superseded by documents or reports subsequently filed or
furnished.
On July 20, 2004 and June 21, 2004, respectively, Sanofi-Synthelabo issued
the two press releases attached hereto as Exhibit 99.1 and Exhibit 99.2, each of
which is incorporated herein by reference.
EXHIBIT LIST
Exhibit No. Description
----------- -----------
Exhibit 99.1 Press Release, dated July 20, 2004, confirming filing of ANDA by
Teva Pharmaceuticals
Exhibit 99.2 Press Release, dated July 21, 2004, announcing
Sanofi-Synthelabo's sales figures for First Half of 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Dated: July 21, 2004 SANOFI-SYNTHELABO
By: /s/ Marie-Helene Laimay
----------------------------------
Name: Marie-Helene Laimay
Title: Senior Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
Exhibit 99.1 Press Release, dated July 20, 2004, confirming filing of ANDA by
Teva Pharmaceuticals
Exhibit 99.2 Press Release, dated July 21, 2004, announcing
Sanofi-Synthelabo's sales figures for First Half of 2004